Terms: = Lymphoma AND LASP1, ENSG00000002834, 3927, Q14847, MLN50, Lasp-1
3 results:
1. Tumor mutational burden assessment and standardized bioinformatics approach using custom NGS panels in clinical routine.
Dupain C; Gutman T; Girard E; Kamoun C; Marret G; Castel-Ajgal Z; Sablin MP; Neuzillet C; Borcoman E; Hescot S; Callens C; Trabelsi-Grati O; Melaabi S; Vibert R; Antonio S; Franck C; Galut M; Guillou I; Halladjian M; Allory Y; Cyrta J; Romejon J; Frouin E; Stoppa-Lyonnet D; Wong J; Le Tourneau C; Bièche I; Servant N; Kamal M; Masliah-Planchon J
BMC Biol; 2024 Feb; 22(1):43. PubMed ID: 38378561
[TBL] [Abstract] [Full Text] [Related]
2. MiR-665 suppresses the progression of diffuse large B cell lymphoma (DLBCL) through targeting LIM and SH3 protein 1 (lasp1).
Wang Y; Guo D; Li B; Wang Y; Wang B; Wang Z; Wang M; Teng Q
Leuk Res; 2022 Jan; 112():106769. PubMed ID: 34875555
[TBL] [Abstract] [Full Text] [Related]
3. Outcomes and Predictors of Mortality for Patients with Acute Leukemia Admitted to the Intensive Care Unit.
Kraguljac AP; Croucher D; Christian M; Ibrahimova N; Kumar V; Jacob G; Kiss A; Minden MD; Mehta S
Can Respir J; 2016; 2016():3027656. PubMed ID: 27445524
[TBL] [Abstract] [Full Text] [Related]
